Canadian medicines with clinical-trial evidence for a new indication

53 of the 932 medicines with a CaTxGNN report have a TxGNN-predicted new indication graded at evidence level L1 or L2 (12 at L1, 41 at L2), meaning clinical-trial evidence (randomized trials, Phase 2–3 trials or systematic reviews) was found for it.

The medicines come from Health Canada’s Drug Product Database (DPD), with each product’s DIN status shown in the drug report; the list reflects the drug reports as last updated on 2026-11-06.

Trial evidence for a predicted indication is not proof of efficacy. Every candidate below still requires clinical validation and regulatory review before any clinical use.

---

Medicines with trial evidence (L1–L2)

Drug	Predicted new indication	Evidence level	Registered trials cited (NCT)
Acetylcysteine	Thrombotic disease	L1 (with caveat)	7
Bendamustine	Mantle cell lymphoma	L1	10
Bromfenac	Eye disease	L1	10
Busulfan	Myelodysplastic syndrome	L1 (with caveat)	11
Clofarabine	myeloid leukemia	L1	10
Clomipramine	Anxiety disorder	L1 (with caveat)	8
Dapsone	pneumocystosis	L1	9
Doxorubicin	Ewing sarcoma	L1	10
Ketamine	Headache disorder	L1 (with caveat)	9
Ketorolac	Headache disorder	L1	10
Peginterferon Alfa-2A	Hepatitis E virus infection	L1	10
Ribavirin	Chronic hepatitis B virus infection	L1 (with caveat)	10
Atorvastatin	HIV infectious disease	L2	10
Brentuximab Vedotin	Follicular lymphoma	L2 (with caveat)	11
Bupropion	attention deficit-hyperactivity disorder	L2	6
Cefprozil	urinary tract infection (disease)	L2	0
Citalopram	Obsessive-compulsive disorder	L2	4
Clozapine	Manic bipolar affective disorder	L2	1
Dasatinib	Ewing sarcoma	L2 (with caveat)	2
Desoximetasone	Alopecia areata	L2	0
Diazepam	Insomnia (disease)	L2	0
Docetaxel	Ewing sarcoma	L2	8
Fludarabine	Plasma cell myeloma	L2 (with caveat)	12
Goserelin	Amenorrhea (disease)	L2 (with caveat)	1
Hydrocortisone	Alopecia areata	L2	1
Hydrocortisone Acetate	Alopecia areata	L2	1
Ledipasvir	Hepatitis B virus infection	L2	5
Lenalidomide	Myeloid leukemia	L2	11
Levonorgestrel	Acne (disease)	L2	0
Mefenamic Acid	Headache disorder	L2	0
Midazolam	Insomnia	L2	2
Moclobemide	Agoraphobia	L2	0
Montelukast	Bronchitis	L2	10
Mycophenolate Mofetil	HIV infectious disease	L2 (with caveat)	4
Nepafenac	Eye disease	L2	10
Nortriptyline	Attention deficit-hyperactivity disorder	L2	0
Ofatumumab	Follicular lymphoma	L2	12
Oxaliplatin	Malignant pleural mesothelioma	L2	3
Pimecrolimus	Seborrheic dermatitis	L2	1
Prednisolone	Alopecia areata	L2	0
Prednisone	Alopecia areata	L2	0
Propofol	Migraine disorder	L2	3
Regorafenib	Liposarcoma	L2	1
Risankizumab	Dermatitis	L2	2
Sodium Oxybate	Insomnia	L2	3
Sodium Tetradecyl Sulfate	Esophageal varices with bleeding	L2	0
Solriamfetol	Attention deficit-hyperactivity disorder	L2	5
Sucralfate	Duodenogastric reflux	L2	0
Sunitinib	Liposarcoma	L2	2
Tacrolimus	Seborrheic dermatitis	L2 (with caveat)	2
Tizanidine	Migraine disorder	L2	2
Ustekinumab	Dermatitis	L2 (with caveat)	6
Vinorelbine	Ewing sarcoma	L2	3

How to read this list

• Evidence level follows the site’s criteria: L1 = Multiple Phase 3 RCTs / systematic reviews; L2 = Single RCT or multiple Phase 2 trials. “(with caveat)” means the drug report qualifies the grade; read the note in the report before relying on it.
• Predicted new indication is the main prediction shown in each drug report. Indications and contraindications already recorded in the TxGNN knowledge graph are excluded, but some predictions may still overlap an established use; the report explains this where it applies.
• Registered trials cited counts the ClinicalTrials.gov (NCT) numbers cited in the drug report. Reports cite a selection of the trials found; 0 means the report cites no registered trial, and its literature evidence section shows the basis for the grade.
• For all levels and the full method, see High Evidence (L1-L2), All Drugs and the methodology.

---

Disclaimer
This report is for academic research reference only and does not constitute medical advice. Always follow your physician's instructions; never adjust medication on your own. Any drug repurposing decision requires full clinical validation and regulatory review.

Reviewed by: 藥提醒科技有限公司 (yao.care)